Lorenzo Di Cesare Mannelli
Overview
Explore the profile of Lorenzo Di Cesare Mannelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
293
Citations
3568
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Libero M, Lucarini E, Recinella L, Ciampi C, Veschi S, Piro A, et al.
Phytother Res
. 2024 Jun;
38(8):4177-4188.
PMID: 38923108
Inflammatory bowel disease (IBD) is a morbid condition characterized by relapsing-remitting inflammation of the colon, accompanied by persistent gut dysmotility and abdominal pain. Different reports demonstrated biological activities of aged...
12.
Arias H, Micheli L, Rudin D, Bento O, Borsdorf S, Ciampi C, et al.
Biomed Pharmacother
. 2024 Jun;
177:116867.
PMID: 38889634
The aim of this study was to determine the anti-hypersensitivity activity of novel non-hallucinogenic compounds derived from iboga alkaloids (i.e., ibogalogs), including tabernanthalog (TBG), ibogainalog (IBG), and ibogaminalog (DM506), using...
13.
Di Salvo C, DAntongiovanni V, Benvenuti L, Fornai M, Valdiserra G, Natale G, et al.
J Drug Target
. 2024 Jun;
32(8):953-963.
PMID: 38864378
Nowadays, the pharmacological management of visceral hypersensitivity associated with colitis is ineffective. In this context, targeting purinergic P2X4 receptor (P2X4R), which can modulate visceral pain transmission, could represent a promising...
14.
Micheli L, Parisio C, Lucarini E, Vona A, Toti A, Pacini A, et al.
J Exp Clin Cancer Res
. 2024 Apr;
43(1):120.
PMID: 38650002
No abstract available.
15.
Nobili S, Micheli L, Lucarini E, Toti A, Ghelardini C, Di Cesare Mannelli L
Pharmacol Ther
. 2024 Apr;
258:108649.
PMID: 38615798
Current epidemiological data estimate that one in five people suffers from chronic pain with considerable impairment of health-related quality of life. The pharmacological treatment is based on first- and second-line...
16.
Giannaccare G, Vaccaro S, Borselli M, Rossi C, Scalzo G, Scalia G, et al.
J Clin Med
. 2024 Apr;
13(5).
PMID: 38592312
(1) : Dry eye disease (DED) is a multifactorial ocular surface disease characterized by an imbalance in ocular surface homeostasis, and tear substitutes constitute the first line of treatment. The...
17.
Micheli L, Lucarini E, Corti F, Ciccocioppo R, Calo G, Rizzi A, et al.
Eur J Pharmacol
. 2024 Mar;
970:176497.
PMID: 38499455
No abstract available.
18.
Vlasakova K, Tsuchiya T, Garfinkel I, Ruth M, Tyszkiewicz C, Detwiler T, et al.
Front Neurosci
. 2024 Jan;
17:1285359.
PMID: 38292901
Background: Target organ toxicity is often a reason for attritions in nonclinical and clinical drug development. Leveraging emerging safety biomarkers in nonclinical studies provides an opportunity to monitor such toxicities...
19.
Flori L, Montanaro R, Pagnotta E, Ugolini L, Righetti L, Martelli A, et al.
Biomedicines
. 2023 Dec;
11(12).
PMID: 38137502
Modulation of mitochondrial K channels represents a pharmacological strategy to promote cardioprotective effects. Isothiocyanates emerge as molecules capable of releasing hydrogen sulfide (HS), an endogenous pleiotropic gasotransmitter responsible for anti-ischemic...
20.
Casertano M, Esposito E, Bello I, Indolfi C, Putra M, Di Cesare Mannelli L, et al.
Mar Drugs
. 2023 Dec;
21(12).
PMID: 38132963
Hydrogen sulfide (HS) is a signaling molecule endogenously produced within mammals' cells that plays an important role in inflammation, exerting anti-inflammatory effects. In this view, the research has shown a...